Financial ConcernsManagement is making early progress extending the cash runway with ~$850MM currently in hand, but there is potential for ~$400MM in annual burn, which is well above management targets.
Market Penetration RisksAdditional financing will likely be required to build out commercial infrastructure for successful market penetration.
Regulatory And Reimbursement ChallengesBroad reimbursement and adoption hinge on the NHS-Galleri readout and subsequent FDA approval, which are several years away.